Purpose Metformin may have a role in reducing the incidence of colorectal cancer (CRC)
and improving survival outcome. This meta-analysis explored the effect of metformin use on …

Aim We carried out this meta-analysis on all published studies to estimate the overall cancer
risk of the use of metformin in T2DM patients. Methods We searched the PubMed, Embase …

BACKGROUND: Diabetes mellitus is a systemic disorder associated with inflammation and
oxidative stress which may target many organs such as the kidney, retina, and the vascular …

Background Diabetes mellitus has been associated with increased breast cancer (BC) risk;
however, the magnitude of this effect is uncertain. This study focused on BC risk for women …

Objective We aim to evaluate the relationship between the use of metformin and the risk of
pancreatic cancer in type 2 diabetes patients. Method We systematically searched the …

Abstract Background Antidiabetic medications (ADMs) may modify prostate cancer (PCa)
risk in patients with diabetes mellitus (DM). Accordingly, the current study assessed the …

Background Many studies have investigated the prognosis of nonalcoholic fatty liver disease
(NAFLD); however, most studies had a relatively short follow-up. To elucidate the long-term …

Background The views regarding the associations between metformin use and
hepatocellular carcinoma (HCC) among diabetes mellitus (DM) patients are divisive. Thus …

Whether metformin is a protective factor of colorectal cancer (CRC) among CRC patients is
still not entirely clear. Thus, we conducted this systemic review and meta-analysis to provide …

Preclinical studies have suggested the antitumorigenic properties of metformin on prostate
cancer; results from epidemiological studies remain contradictory. We aim to investigate the …